QIAGEN partners with U.K. to expand biomarker research in Manchester

“This is a hugely important step change for Greater Manchester’s already strong life sciences sector. The new health innovation campus, with QIAGEN at its heart, will support the continued growth of businesses which are driving the future shape of medicine and health care, and cement our position as a world-leader in precision medicine,” said Rowena Burns, Chair of Health Innovation Manchester and Manchester Science Partnerships. “This is precisely what Health Innovation Manchester was set up to do, and combined with our devolved health and social care system, places us in an incredibly strong position to address the health challenges of the population.”

“This will help confirm Manchester as a world leader in this vital emerging industry with enormous growth potential. This is an opportunity that as a city we cannot afford to miss. It’s a win-win – not just creating a raft of new highly skilled health science jobs and an economic boost but crucially also opening up revolutionary new health benefits for people here. Manchester’s future success depends on building on our distinctive strengths and life sciences definitely falls into that category,” said Sir Richard Leese, Leader of Manchester City Council.

The new Genomic Health Innovation Campus aims to attract a cluster of synergistic companies to Manchester, in collaboration with academic and clinical organizations, to drive pioneering research and development – as well as to secure employment growth in the life science and healthcare fields. Financial contributions will come from public entities in the U.K., advancing national and regional strategies to transform the economy with R&D and technology-driven enterprises. The genomics campus will be built on the Manchester University NHS Foundation Trust’s clinical site in the Corridor Manchester innovation district, adjacent to hospitals, the University of Manchester, and other research and commercial assets.

“These partnerships leverage QIAGEN’s rich expertise in Manchester to accelerate innovation as a basis for the development of valuable molecular tests. This is a true win-win situation, bringing together QIAGEN, the global leader in Sample to Insight solutions, with important intellectual assets in the U.K. to accelerate molecular biomarker research and subsequent development of new and promising diagnostic assays,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “We expect this collaborative initiative to serve as an innovation incubator to support translating genomic biomarkers into clinical use and ultimately to yield benefits for our customers and patients everywhere who need advanced diagnostic insights.”

“Creating a globally-leading genomic campus contributes directly to the industrial strategy of the United Kingdom, as well as innovation-driven growth in employment for the Manchester region. We have deep human resources, with the knowledge and technologies to supercharge R&D in the life sciences – and create new solutions for patients and the healthcare system,” said Thierry Bernard, Senior Vice President and head of QIAGEN’s Molecular Diagnostics Business Area.

QIAGEN’s Manchester site remains central to the company’s short-term and long-term strategic plans for global innovation and development. QIAGEN currently has about 270 employees in Manchester and is committed to further growth. The Manchester operation plans to move into a new state-of-the-art facility in 2020, Citylabs 2.0, at the heart of the new genomics campus.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected sales, adjusted net sales and adjusted diluted earnings per share results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers‘ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors‘ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).